Technology
Our Facility
Starton’s Development Facility, located in Paramus NJ, drives activities such as formulation development, analytical and preclinical testing, and clinical trial material production to support GMP Phase 1 clinical trials.
Our drug delivery platform technology provides a controlled, sustained release over multiple days.
The use of continuous delivery allows for lower peaks and higher troughs which provide therapeutic blood levels for the entirety of the dosing interval whereas once-daily oral dosing is associated with sub-therapeutic blood levels during each day’s dosing. Importantly, the total daily exposure can be 55-70% lower than once-daily oral administration with a resultant AUC similarly lower than oral therapy. The expected result of this “flattening of the curve” of blood levels is better tolerability through lower exposure and improved efficacy through continuous maintenance of the minimum immunomodulatory concentration of the treatment interval.
traditional delivery vs continuous delivery
Short half-life drugs wear off quickly and leave cancer cells to recover or create resistance between dosing intervals
Short half-life drugs require a high initial dose, resulting in high blood levels potentially leading to adverse reactions
Starton uses continuous delivery systems to improve outcomes and quality of life